Working… Menu

IL-26 and Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01889641
Recruitment Status : Terminated
First Posted : June 28, 2013
Last Update Posted : September 8, 2017
Information provided by (Responsible Party):
University Hospital, Strasbourg, France

Brief Summary:
Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.

Condition or disease
Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling

Layout table for study information
Study Type : Observational
Actual Enrollment : 23 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique
Actual Study Start Date : February 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

Patients with lupus
Patients with lupus (four levels of activity disease)
healthy volunteers
Subjects controls

Primary Outcome Measures :
  1. Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
patient and healthy volunteers

Inclusion Criteria:

  • diagnostic of Lupus according to ACR criteria ( four criteria are necessary)
  • age > 18 years old

Exclusion Criteria:

  • treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01889641

Layout table for location information
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, Bas Rhin, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Layout table for additonal information
Responsible Party: University Hospital, Strasbourg, France Identifier: NCT01889641    
Other Study ID Numbers: 5504
First Posted: June 28, 2013    Key Record Dates
Last Update Posted: September 8, 2017
Last Verified: September 2017